SPX3,825.33
1.06%Positive
IXIC11,127.84
0.90%Positive
DJI31,097.26
1.05%Positive
STOXX407.13
0.02%Negative
FTSE7,168.65
0.01%Negative
N22525,935.62
1.73%Negative

Gracell Biotechnologies Inc

GRCL.OQ

Official Data Partner

Latest Trade: trading lower5.1USD
Change: -0.4
% Change: 7.27%Negative

Day Range

4.93 - 5.52

52-Week Range

1.68 - 15.00

Previous Close: 5.50
Open: 5.39
Volume: 10,688.00
3 Month Average Trading Volume: 3.04
Shares Out (Mil): 337.50
Market Cap: 353.21
Forward P/E: -16.19
Dividend Yield: -99,999.99

Key Statistics

1.6 mean rating - 5 analysts

Sell

Hold

Buy

P/E Excl. Extra Items (TTM): -99,999.99
Price To Sales (TTM): 6,465.83
Price To Book (Quarterly): 1.17
Price To Cash Flow (Per Share TTM): -99,999.99
Total Debt/Total Equity (Quarterly): 5.76
Long Term Debt/Equity (Quarterly): 2.82
Return On Investment (TTM): -34.36
Return On Equity (TTM): -32.06

2021 (millions USD)

About Gracell Biotechnologies Inc

Company Information

Gracell Biotechnologies Inc is a China-based clinical-stage biopharmaceutical company focused on discovering and developing cell therapies for the treatment of cancers. The Company is primarily focused on disrupting conventional approaches to chimeric antigen receptor (CAR) thymus (T) cell therapies by leveraging its technology platforms FasTCAR and TruUCAR. With FasTCAR, the Company is able to deliver younger, less exhausted T cells for autologous cell therapies with enhanced activities and next-day manufacturing. With TruUCAR, the Company is able derive T cells from non-human leukocyte antigen (HLA)-matched healthy donors to generate allogeneic CAR-T cell therapies. The Company is levering its technology platform to develop various drug candidates, including GC012F, GC019F, GC007F, GC027 and GC007g.